Evidence map›Paper›PMID 36367591›Full record

ArticleNano-micro letters2022

Bacterial Metabolism-Initiated Nanocatalytic Tumor Immunotherapy.

Wencheng Wu, Yinying Pu, Shuang Gao, Yucui Shen, Min Zhou, Heliang Yao, Jianlin Shi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano-micro letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Review
  3. Micro/Nano-Motors for Enhanced Tumor Diagnosis and Therapy.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Oncoimmunology · 2024
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Wencheng WuThe State Key Lab of High Performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Sciences; Research Unit of Shanghai Nanocatalytic Medicine in Specific Therapy for Serious Disease, Chinese Academy of Medical Sciences (2021RU012), Shanghai, 200050, People's Republic of China.
Yinying PuDepartment of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Tongji University School of Medicine, Shanghai, 200072, People's Republic of China.
Shuang GaoDigestive Endoscopy Center, Shanghai Fourth People's Hospital to Tongji University, Shanghai, 200081, People's Republic of China.
Yucui ShenDigestive Endoscopy Center, Shanghai Fourth People's Hospital to Tongji University, Shanghai, 200081, People's Republic of China.
Min ZhouDigestive Endoscopy Center, Shanghai Fourth People's Hospital to Tongji University, Shanghai, 200081, People's Republic of China. crown_zhou@hotmail.com.
Heliang YaoThe State Key Lab of High Performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Sciences; Research Unit of Shanghai Nanocatalytic Medicine in Specific Therapy for Serious Disease, Chinese Academy of Medical Sciences (2021RU012), Shanghai, 200050, People's Republic of China.
Jianlin ShiThe State Key Lab of High Performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Sciences; Research Unit of Shanghai Nanocatalytic Medicine in Specific Therapy for Serious Disease, Chinese Academy of Medical Sciences (2021RU012), Shanghai, 200050, People's Republic of China. jlshi@mail.sic.ac.cn.
Tongji University · CNShanghai Institute of Ceramics · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The low immunogenicity of tumors remains one of the major limitations of cancer immunotherapy. Herein, we report a bacterial metabolism-initiated and photothermal-enhanced nanocatalytic therapy strategy to completely eradicate primary tumor by triggering highly effective antitumor immune responses. Briefly, a microbiotic nanomedicine, designated as Cu

Indexed as

Bacterial metabolismImmunotherapyIn situ nanocatalytic therapy

Identifiers

PMID36367591
PMCPMC9652197
OpenAlexW4309159261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.